If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Dose adjustment may be needed when transitioning from another insulin to Humalog® (insulin lispro). Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased (Humalog Package Insert, 2015).
Enclosed Prescribing Information
Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.
Date of Last Review: March 18, 2017